eGFR (mL/min/1.73 m2)
60 and above
Dosing approach
Standard dosing
Key reminders
Review nephrotoxic meds and repeat labs yearly.
Prescribing
Renal dose adjustment summary
High-level dosing considerations by eGFR with safety reminders.
Last reviewed 2026-01-05|renal | safety | medication
Editorial feedback
Suggest an update
Flag outdated guidance or propose revised wording for this page. Do not include PHI or patient identifiers.
Jump to
Dosing quick reference
eGFR (mL/min/1.73 m2)
45-59
Dosing approach
Caution with renally cleared meds
Key reminders
Consider lower starting doses and closer monitoring.
eGFR (mL/min/1.73 m2)
30-44
Dosing approach
Dose reduce or extend interval
Key reminders
Avoid NSAIDs; reassess metformin, DOACs, and opioids.
eGFR (mL/min/1.73 m2)
Below 30
Dosing approach
Avoid or specialist-guided dosing
Key reminders
Confirm dosing with pharmacy or nephrology.
eGFR (mL/min/1.73 m2)
Dialysis
Dosing approach
Dialysis-specific dosing
Key reminders
Check timing around dialysis sessions.
| eGFR (mL/min/1.73 m2) | Dosing approach | Key reminders |
|---|---|---|
| 60 and above | Standard dosing | Review nephrotoxic meds and repeat labs yearly. |
| 45-59 | Caution with renally cleared meds | Consider lower starting doses and closer monitoring. |
| 30-44 | Dose reduce or extend interval | Avoid NSAIDs; reassess metformin, DOACs, and opioids. |
| Below 30 | Avoid or specialist-guided dosing | Confirm dosing with pharmacy or nephrology. |
| Dialysis | Dialysis-specific dosing | Check timing around dialysis sessions. |
Contraindications
- Avoid standard dosing assumptions when eGFR is below medication-specific safety thresholds.
- Avoid nephrotoxic combinations during acute kidney injury risk periods when alternatives exist.
- Avoid finalizing high-risk regimens without drug-specific reference confirmation.
Renal and hepatic considerations
- This is a high-level summary; always verify with product monographs or RxTx.
- Adjust for acute kidney injury and rapid changes in creatinine.
- Integrate hepatic function review for medications with mixed renal/hepatic clearance.
Pregnancy and lactation cautions
- Pregnancy changes renal physiology and can alter drug exposure; use pregnancy-specific references.
- During lactation, confirm medication transfer risk and infant safety context.
- Seek specialist or pharmacist support when maternal-fetal risk is uncertain.
Monitoring checkpoints
- Recheck renal labs after clinically meaningful medication changes or acute illness.
- Coordinate with pharmacy for complex polypharmacy.
- Document dose rationale and planned follow-up interval in the chart.
Stop or escalate criteria
- Hold or stop medications when rapid creatinine rise, severe electrolyte disturbance, or toxicity appears.
- Escalate when eGFR is below 30 mL/min/1.73 m2, dialysis is involved, or dosing references conflict.
- Escalate urgently if clinical instability develops while dosing uncertainty remains unresolved.